Epicardial fat thickness is associated to type 2 diabetes mellitus in Korean men: a cross-sectional study

Hyejin Chun¹, Eunkyung Suh², A Ri Byun³, Hae Ran Park³ and Kyung Won Shim³*

Abstract

Background: Visceral fat, including epicardial fat (EF) is recognized as a responsible factor of cardiovascular disease. The aim of this study was to investigate the relationship between EF and diabetes in Korean men.

Methods: EF thickness was measured in the left main coronary artery fat tissue (LMCA-fat) by low-dose chest CT scans in 1,048 Korean men (age above 20 years). LMCA-fat values were divided into quartiles and the prevalence of diabetes was analyzed based on the quartiles of LMCA-fat values using logistic regression.

Results: There were significant correlations between LMCA-fat and body mass index (r = 0.169, p = 0.004), waist circumference (r = 0.172, p < 0.001), fasting glucose (r = 0.106, p = 0.037) and HbA1c (r = 0.176, p < 0.001). The patients in the higher LMCA-fat quartiles were associated with higher prevalence of diabetes (p for trend <0.001). Even after adjustment for multiple covariates, this association still remained statistically significant (p for trend = 0.022). The highest LMCA-fat quartile group was significantly associated with diabetes compared to the lowest quartile group. (OR = 3.26, 95% CI = 1.17-9.12).

Conclusion: These findings indicate that increased EF thickness is independently associated with the prevalence of diabetes in Korean men.

Keywords: Epicardial fat tissue, Diabetes, Low-dose chest CT, Visceral fat

Background

Obesity and insulin resistance are important risk factors of diabetes and atherosclerosis [1]. In particular visceral fat is known to influence insulin resistance and the incidence of diabetes. Therefore, visceral fat has been found to be an independent risk factor of metabolic syndrome, diabetes, and cardiovascular diseases [2]. Thus, recent studies have shown that the visceral fat might have a role in the pathogenesis of cardiovascular disease. However, most studies on visceral fat focus on the abdominal area only. In fact, studies on the association of visceral fat in other regions of the body with diabetes are insufficient.

Epicardial fat (EF) is defined as the adipose tissue enclosed in the visceral pericardium including the fat surrounding coronary arteries [3]. EF originates from brown fat and has the same origin as visceral fat, which shares much of the pathophysiological properties of visceral fat [4]. Also EF secretes pro-inflammatory and anti-inflammatory cytokines and chemokines that directly contacts the surroundings of the coronary artery [3]. Although EF accounts for only 1% of total body fat, it has been suggested to influence the development of coronary atherosclerosis due to its endocrine and paracrine activities. Therefore, interest in EF is on the rise. Visceral fat, especially EF has been shown to have close correlation with insulin resistance [5]. For that reason, EF could be a major factor that influences metabolic diseases such as metabolic syndrome and cardiovascular diseases such as coronary artery disease. Several studies have reported the correlation between EF and insulin resistance [6-12]. Based on these study results, the hypothesis that EF may contribute to unfavorable metabolic risk profiles has been suggested [11].

Low dose chest computed tomography (LDCT) is a useful tool for lung cancer screening in health promotion centers. LDCT is frequently used these days due to the advantage that it does not require 6 hour fasting and...
the radiation exposure from LDCT is much less than the contrast-enhanced computed tomography (CT). EF thickness area and volume can be accurately measured by LDCT [4]. Among them, EF thickness can be most easily measured, has little difference in repeated measurement and EF thickness shows close correlation with the total EF volume [13]. Recently, many researchers have been interested in EF thickness and many studies were done. Although EF is distributed asymmetrically between the coronary artery and ventricle or between the ventricles, there were no differences by the measurement methods (ultrasonography or 3-dimensional heart computed tomography) in the thickness of EF in previous studies [14-16]. EF thickness can be measured at the level of the three main coronary arteries (right, left anterior descending and left circumflex arteries) or at the right ventricular free wall [4]. EF thickness, especially measured around the left main coronary artery-fat (LMCA-fat) has been used in many studies since it can be most simply measured using just few image slices. In this study, we investigate the association of LDCT-measured LMCA-fat thickness with the prevalence of type 2 diabetes in Korean men.

Method

Study population
The present study was a retrospective cross-sectional study to examine the association between EF and prevalence of diabetes in Korean men participating in a medical health check-up program at the health promotion center of Ewha Womans University School of Medicine Seoul, Korea. The subjects of this study were 1,101 adult males aged 20 or older who received LDCT scans for lung cancer screening between January 2011 and June 2012. Diabetes was defined as fasting blood glucose of more than 126 mg/dL, or HbA1c value of more than 6.5%, or current use of oral hypoglycemic agents or insulin [17]. Among the 1,101 participants, 53 men who had history of malignancy or cardiovascular disease and whose presence of diabetes could not be determined were excluded from the study. Accordingly, 1,048 participants were included in the final analysis. This study was approved by the Institutional Review Board of Ewha Woman’s University Mokdong Hospital (IRB file number: EUMC 2014-05-022-001). Informed consent was obtained from all participants.

Study method
Study data included medical history physical examination, information provided by questionnaires, anthropometric measurements and laboratory measurements. Medical history was assessed by the examining physicians. All the participants were asked about health-related behaviors including alcohol consumption and smoking. Questions about alcohol consumption included frequency of alcohol intake per week and usual amount of alcohol intake per day. Participants were considered as current smokers when reported to have smoked within the last six months, and nonsmokers when reported to have not smoked for the last six months or who have never smoked [18]. Their heights were measured down to the 0.1 cm unit with the subjects wearing a light gown for health examination, with their heels attached to the ground, and their back straightened. Their weights were measured wearing a light gown of less than 0.1 kg, after an overnight 8 hour fasting and after urination. Body mass index (BMI) was defined as their weight (kg) divided by the square of their height (m). Waist circumference (WC) was measured down to the 0.1 cm unit at the midpoint between the lower rib margin and the iliac crest. After resting for at least 5 minutes, blood pressures were measured using a standardized mercury sphygmomanometer at the right brachial artery while sitting on a chair. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded as the first and fifth Korotkoff phases, respectively. The definition of hypertension followed those of NCEP ATPIII, JNC 8 (The Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure). According to the JNC-8 guidelines, hypertension was defined as cases of a systolic blood pressure of 140 mmHg or higher or a diastolic blood pressure of 90 mmHg or higher which were measured during the health examination or taking antihypertensive agent after being diagnosed with hypertension [19]. If the blood pressure was abnormal at first measurement, they were measured once more after resting for 10 minutes and the latter blood pressure was used as study data.

Laboratory measure
For the blood tests peripheral venous samples were collected after fasting for at least 8 hours. Total cholesterol, triglyceride (TG), low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma galutamyltransferase (GGT), creatinine, fasting blood glucose, and hemoglobin A1c (HbA1c) were measured. These levels were measured using Bayer Reagent Packs (Bayer HealthCare, Tarrytown, NY, USA) with an automated chemistry analyzer (ADVIA 1650 Autoanalyzer Bayer Diagnostics Leverkusen, Germany). The clinical laboratory has been accredited and participates annually in inspections and surveys done by the Korean Association of Quality Assurance for Clinical Laboratories.

LMCA-fat thickness measurement
In this study LDCT scan was taken using a 128 multi-detector CT scanner (SOMATOM Definition Flash 128, Siemens Medical Solution, Forchheim, Germany). Each
scan was obtained during a single breath-hold. The thickness of each slice was 2 mm, average scan duration was 4–6 seconds and the tube voltage was low dose (120 kVp, 20 eff.mAs). EF was defined as adipose tissue between the surface of the myocardium and the visceral layer of the pericardium. The LMCA-fat thickness was measured at the longest vertical length of EF around the left main coronary artery at the origin and was measured by the same doctor. Since a single slice image is 2 mm in thickness, the longest length of LMCA-fat thickness was measured by looking at approximately 15 slices around the LMCA. LMCA-fat thickness was measured manually by one doctor and fat pixels were identified using threshold attenuation values of −30 to −200 HU [20].

Statistical analysis
Data in the text and tables were expressed as mean ± standard deviation (SD) or medians (interquartile range) for continuous variables and percentages of the number for categorical variables. Participants were divided into quartiles on the basis of LMCA-fat thickness as follows: quartile 1 (Q1) LMCA-fat thickness < 12.3 mm; quartile 2 (Q2) LMCA-fat thickness 12.3 to 15.4 mm quartile 3 (Q3) LMCA-fat thickness 15.4 to 18.7 mm; and quartile 4 (Q4) LMCA-fat thickness ≥ 18.7 mm. One-way ANOVA and \( \chi^2 \)-test were performed to analyze the statistical differences among the characteristics of the participants according to the quartile groups of LMCA-fat thickness. To analyze the correlation between LMCA-fat thickness and the related variables, Pearson correlation analysis was performed. Linear-by-linear association was used to analyze the differences in the prevalence of diabetes by LMCA-fat thickness quartiles with \( p \) for trend. Compared to the lowest quartile of LMCA-fat thickness, the Odds ratios (ORs) of the highest 3 quartiles of LMCA-fat thickness were calculated using logistic regression. Also, logistic regression was used to analyze the independent risk of LMCA-fat thickness on diabetes after adjusting the clinical variables related to diabetes such as age, BMI, SBP, DBP, AST, ALT, TG, HDL cholesterol, and LDL cholesterol. LMCA-fat thickness in the diabetes group (17.6 ± 6.7 mm) was significantly higher than in the non-diabetes group (14.4 ± 5.9 mm) (\( p < 0.001 \)).

Table 2 shows clinical characteristics according to the quartile groups of LMCA-fat thickness. As expected age, hypertension, BMI, WC, and blood pressure of the participants tended to increase according to the quartile groups. The prevalence of diabetes also tended to increase according to the quartile groups of LMCA-fat thickness level (\( p < 0.001 \)). All clinical variables showed statistically significant differences between the four groups except for recent smoking status. The higher LMCA quartiles had less favorable metabolic profiles. In the laboratory findings, there were significant linear trends across the quartiles of LMCA except for total cholesterol and LDL-cholesterol. Age, prevalence of hypertension, BMI, WC, blood pressure, AST, ALT, GGT, Triglyceride, fasting glucose, HDL cholesterol and HbA1c tended to increase as the LMCA fat thickness level increased. Differences in the prevalence of diabetes were examined through \( p \) for trend analysis according to the LMCA-fat thickness quartiles and are presented at the bottom of Table 2. A total of 141 men were identified to have diabetes by fasting glucose, HbA1c and medical history among the 1,048 participants. When the LMCA fat thickness was divided into four quartiles, the prevalence of diabetes was 6.9% (18 participants) in quartile 1, 9.5% (25 participants) in quartile 2, 16.4% (43 participants) in quartile 3 and 21.3% (55 participants) in quartile 4. In other words, there was a significant linear trend in the prevalence of diabetes across the quartiles of LMCA-fat thickness level. As expected, the prevalence of diabetes tended to increase depending on the LMCA fat thickness (\( p \) for trend < 0.001).

To analyze the correlation between LMCA fat thickness and the related variables a Pearson correlation analysis was performed (Table 3). LMCA fat thickness correlated with BMI (\( r = 0.169 \), \( p = 0.004 \)) and WC (\( r = 0.172 \), \( p < 0.001 \)). Fasting glucose (\( r = 0.105 \), \( p = 0.037 \)) and HbA1c (\( r = 0.176 \), \( p < 0.001 \)) showed significant positive correlation with the LMCA fat thickness. Age, blood pressure and most laboratory findings except for fasting glucose and HbA1c did not have significant correlations with LMCA fat thickness.

The unadjusted OR of diabetes were 1.43 (95% CI = 0.76-2.69) in quartile 2 2.66 (95% CI = 1.49-4.75) in quartile 3 and 3.69 (95% CI = 2.10-6.47) in quartile 4 compared to quartile 1 (Table 4). Even after adjustment for age, BMI, WC, TG, systolic BP, GGT, ALT, smoking status and
Table 1 Baseline characteristics of the study population (n = 1,048)

| Variable          | Overall (n = 1,048) | Diabetes (n = 141) | Non-diabetes (n = 907) | p value* |
|-------------------|---------------------|--------------------|------------------------|----------|
| Age (years)       | 41.3 ± 6.3          | 44.1 ± 7.1         | 40.25 ± 6.9            | <0.001   |
| Smoker (%)        | 217 (20.7)          | 39 (27.7)          | 178 (19.6)             | <0.001   |
| Hypertension (%)  | 187 (17.8)          | 37 (26.2)          | 150 (16.5)             | <0.001   |
| BMI (kg/m²)       | 24.9 ± 7.3          | 26.1 ± 5.7         | 23.7 ± 2.8             | <0.001   |
| WC (cm)           | 88.4 ± 5.6          | 91.2 ± 6.1         | 86.5 ± 7.5             | <0.001   |
| SBP (mmHg)        | 125.3 ± 12.4        | 126.1 ± 10.5       | 124.8 ± 11.4           | 0.024    |
| DBP (mmHg)        | 75.4 ± 9.6          | 77.2 ± 10.1        | 75.1 ± 10.0            | <0.001   |
| AST (IU/L)        | 24.7 ± 7.9          | 26.2 ± 8.5         | 24.2 ± 6.5             | 0.007    |
| ALT (IU/L)        | 26.2 ± 8.1          | 27.5 ± 7.1         | 25.6 ± 9.4             | 0.006    |
| GGT(IU/L)         | 41.5 ± 8.5          | 43.6 ± 8.2         | 40.2 ± 10.1            | <0.001   |
| Total cholesterol (mg/dL) | 189.7 ± 29.5 | 190.1 ± 28.7       | 189.6 ± 30.8           | 0.751    |
| Triglyceride (mg/dL) | 127.6 ± 24.9 | 131.7 ± 25.1       | 127.1 ± 19.9           | <0.001   |
| HDL-C (mg/dL)     | 48.4 ± 10.4         | 48.0 ± 9.8         | 49.6 ± 11.1            | 0.021    |
| LDL-C (mg/dL)     | 119.3 ± 30.3        | 120.4 ± 29.2       | 119.1 ± 33.5           | 0.252    |
| Fasting glucose (mg/dL) | 97.5 ± 20.1 | 103.8 ± 21.5       | 96.1 ± 25.4            | <0.001   |
| HbA1c (%)         | 5.0 ± 1.1           | 6.3 ± 1.2          | 5.7 ± 0.9              | <0.001   |
| LMCA fat (mm)     | 14.9 ± 5.3          | 17.6 ± 6.7         | 14.4 ± 5.9             | <0.001   |

*P value was calculated by ANOVA or chi-square test.
Abbreviation: LMCA. left main coronary artery fat distance measured by low dose chest CT, DM, diabetes mellitus.

Table 2 Clinical characteristics of the study population and LMCA fat quartile

| Variable          | LMCA fat quartile | p value* |
|-------------------|-------------------|----------|
|                  | Q1                | Q2 | Q3 | Q4 |
| Age (years)       | 36.9 ± 9.5        | 40.5 ± 9.2 | 42.6 ± 9.8 | 43.4 ± 10.3  | <0.001 |
| Smoker (%)        | 51 (19.7)         | 47 (18.1) | 41 (15.5) | 39 (15.6) | 80 (30.6) | 0.091 |
| Hypertension (%)  | 34 (12.9)         | 41 (15.5) | 53 (20.4) | 59 (22.4) | 60 (25.6) | 0.001 |
| BMI (kg/m²)       | 23.4 ± 3.9        | 24.7 ± 4.2 | 25.3 ± 3.8 | 26.0 ± 3.1  | 0.014 |
| WC (cm)           | 87.4 ± 5.9        | 88.1 ± 6.7 | 88.9 ± 6.5 | 90.6 ± 7.1  | <0.001 |
| SBP (mmHg)        | 122.6 ± 12.1      | 125.1 ± 12.2 | 125.6 ± 11.6 | 127.7 ± 12.2  | <0.001 |
| DBP (mmHg)        | 744.9 ± 9.3       | 75.6 ± 10.2 | 76.9 ± 10.0 | 78.3 ± 9.5  | <0.001 |
| AST (IU/L)        | 22.3 ± 7.3        | 23.5 ± 8.1 | 25.2 ± 6.9 | 26.4 ± 7.9  | 0.004 |
| ALT (IU/L)        | 22.4 ± 8.2        | 25.5 ± 7.5 | 27.1 ± 9.0 | 27.3 ± 8.3  | 0.010 |
| GGT(IU/L)         | 31.6 ± 9.3        | 36.3 ± 8.6 | 43.5 ± 10.1 | 45.2 ± 11.3  | <0.001 |
| Total cholesterol (mg/dL) | 188.7 ± 33.8 | 191.3 ± 31.7 | 187.6 ± 34.8 | 190.4 ± 35.9  | 0.901 |
| Triglyceride (mg/dL) | 106 ± 21.9 | 116 ± 23.1 | 130 ± 19.4 | 128 ± 21.3  | <0.001 |
| HDL-C (mg/dL)     | 51.5 ± 11.4       | 49.8 ± 10.4 | 48.6 ± 11.5 | 49.5 ± 11.0  | 0.017 |
| LDL-C (mg/dL)     | 121.3 ± 32.3      | 123.4 ± 29.1 | 119.1 ± 33.1 | 119.3 ± 33.6  | 0.214 |
| Fasting glucose (mg/dL) | 90.2 ± 21.8 | 93.8 ± 20.9 | 96.2 ± 22.1 | 97.5 ± 18.6  | <0.001 |
| HbA1c (%)         | 5.8 ± 1.0         | 5.9 ± 0.9 | 6.0 ± 0.8 | 6.1 ± 0.8  | 0.002 |
| Diabetes (%)      | 18 (6.9)          | 25 (9.5)  | 25 (16.4%) | 55 (21.3%) | <0.001 |

*P value was calculated by ANOVA or chi-square test.
Data are presented as mean ± standard deviation.
LMCA fat: left main coronary artery fat distance measured by low dose chest CT; BMI: Body mass index; WC: Waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; AST: asparatate transaminase; ALT: alanine aminotransferase; GGT: gamma galutamyl transferase; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; HBA1c: hemoglobin A1c; DM: diabetes mellitus.
alcohol intake, the prevalence of diabetic in quartile 4 still showed statistically significant higher levels compared with quartile 1. But after adjustment for the above mentioned factors, the OR of diabetes were 1.63 (95% CI = 0.57-4.65) in quartile 2 and 1.51 (95% CI = 0.52-4.39) in quartile 3, respectively. However, we saw that increased LMCA fat thickness was significantly associated with higher odds of type 2 diabetes (p for trend = 0.022).

Discussion
Main results
The result of this study showed significant association between LMCA fat thickness and the prevalence of diabetes in Korean men. In this study the prevalence of diabetes was increased in a dose-dependent manner by increasing quartiles of LMCA-fat thickness (p for trend < 0.001). In other words, the prevalence of diabetes increased as the EF thickness increased. According to the quartiles of LMCA fat thickness, the prevalence of diabetes in quartile 2, quartile 3, and quartile 4 were 1.43 times, 2.66 times, and 3.69 times higher respectively, than that of quartile 1 which has the lowest EF thickness. This indicates that the increase of EF thickness is associated with the increase of diabetes prevalence. This association persisted after adjusting for age, BMI, WC, TG, SBP, GGT, ALT, smoking status and alcohol intake in quartile 4 which has the highest EF thickness.

Potential mechanisms
The relationship between EF and diabetes can be explained in a few ways. First EF is the visceral fat surrounding the heart and is closely correlated with abdominal fat [21]. The relationship can be explained with by the developmental process of the fetus [5]. Both EF and abdominal fat seem to originate from brown fat which has less anti-lipolytic effect of insulin. Thus, EF is expected to have the same biochemical characteristics as abdominal fat and play a key role in the pathogenesis of diabetes and insulin resistance [7]. EF thickness was shown to be significantly and independently associated with left ventricular diastolic dysfunction and inflammation in patients undergoing peritoneal dialysis and these associations might act synergistically in the pathogenesis of unfavorable metabolic profiles [22]. Moreover, it is known that EF secretes inflammation-related materials such as tumor necrosis factor-alpha (TNF-α), interleukine-6 (IL-6), free fatty acids (FFA), plasminogen activator inhibitor-1 (PAI-1) and adiponectin into blood vessels, especially the coronary arteries, thereby influencing diabetes.

### Table 3 Pearson correlation between LMCA fat and clinical parameter

| Variable          | LMCA fat | p value† |
|-------------------|----------|----------|
| Age               | −0.005   | 0.892    |
| BMI               | 0.169    | 0.004    |
| WC                | 0.172    | <0.001   |
| SBP               | 0.064    | 0.145    |
| DBP               | 0.030    | 0.413    |
| AST               | 0.008    | 0.856    |
| ALT               | 0.011    | 0.794    |
| GGT               | 0.023    | 0.453    |
| Total cholesterol | −0.009   | 0.723    |
| Triglyceride      | 0.029    | 0.713    |
| HDL-C             | −0.024   | 0.647    |
| LDL-C             | −0.009   | 0.759    |
| Fasting glucose   | 0.106    | 0.037    |
| Hba1c             | 0.176    | <0.001   |

* r means pearson correlation coefficient. † P value was calculated by pearson correlation.

### Table 4 Odds ratio of diabetes according to LMCA fat quartile*

| Quartile   | Odds ratio (95% Confidence Interval) |
|------------|-------------------------------------|
|            | Unadjusted                          | Multivariate-adjusted model† |
| LMCA       |                                     |                         |
| Quartile 1 | 1.00 (reference)                    | 1.00 (reference)         |
| Quartile 2 | 1.43 (0.76-2.69)                    | 1.63 (0.57-4.65)         |
| Quartile 3 | 2.66 (1.49-4.75)                    | 1.51 (0.52-4.39)         |
| Quartile 4 | 3.69 (2.10-6.47)                    | 3.26 (1.17-9.12)         |

* Data are given as odds ratio (95% confidence intervals) by logistic regression analysis. † Multivariate data are adjusted by age, BMI, Triglyceride, systolic BP, GGT, ALT, smoking status and alcohol intake.

LMCA fat: left main coronary artery fat distance measured by low dose chest CT; BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; AST: asparatate transaminase; ALT: alanine aminotransferase; GGT: gamma galutamyl transferase; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein; Hba1c: hemoglobin A1c.
obesity, and dyslipidemia [23]. In fact, EF surrounding the coronary arteries might secrete adipokines such as adiponectin from ‘outside-to-inside’ into the intima media layer of blood vessels, thereby contributing to inflammation, atherosclerosis and insulin resistance. Considering the circulation system of our body, it is possible to explain that inflammatory cytokines will be delivered to the whole body because the heart supplies blood to the whole body. Increased plasma concentrations of TNF-α, IL-6, FFA, and PAI-1 and decreased concentrations of adiponectin may lead to accelerated atherosclerosis, plaque instability, and arterial thrombosis. Interestingly, a recent study has shown that FABP4 (Fatty acid-binding proteins 4) expressed in adipocytes or macrophages via classical secretion of numerous inflammation-related materials act as an adipokine for the development of insulin resistance [24]. In addition, it has been shown that higher retinol-binding protein 4 (RBP4) and lower glucose transporter 4 (GLUT4) might contribute to an unfavorable metabolic condition including insulin resistance [25]. RBP4 as an adipokine has been shown to induce insulin resistance and GLUT4 to mediate insulin-stimulated glucose uptake in EF. These inflammatory substances of EF are thought to have significant inflammatory and proatherogenic effects. Up to date, studies are not able to reveal the direct effects of EF on cardiovascular diseases and diabetes.

**Comparision with other studies**

Several studies have reported of the association between the EF surrounding coronary arteries and heart and the development of metabolic syndrome and coronary atherosclerosis. Petra M. Gorter et al. reported that epicardial fat and pericoronary fat are associated with the existence of obesity and metabolic syndrome in patients with coronary artery disease [13]. Iacobelli G et al. revealed that EF measured by transthoracicechocardiography could be a potential risk factor for explaining fasting blood glucose disorder [21]. Although Iacobelli G et al. showed limited results on the correlation between EF and fasting blood glucose [21], our study is meaningful in that the association between EF and the prevalence of diabetes was examined directly. When compared with other studies our study results show a relatively low correlation between BMI and EF thickness (r = 0.169, p value = 0.004). This may be due to the fact that the participants were from health check-ups, so they were much interested in their health and also to the fact that they were relatively young. The reason that other studies have shown a more higher association with BMI may be due to the fact that in most studies researchers investigated EF of patients with coronary heart disease [8,9,13,17,26] or gestational diabetes [27]. In contrast, some studies reported that EF was significantly higher in patients with coronary artery disease or left ventricular diastolic dysfunction but BMI had no statistical significance. Despite this study being consisted of more young and healthy people, we showed significant association between EF thickness and the prevalence of diabetes in Korean men after adjustment for BMI and WC. This is meaningful in that the participants of our study were those without previous heart diseases. The important point is that high EF was a more important factor than high weight or high visceral fat in healthy Korean men even though the correlation coefficient r value was lower than other studies.

**Limitations of this study**

Nevertheless some limitations need to be taken into account as well. First, the pathophysiological effect of EF on predisposition to diabetes was not investigated. In this cross-sectional study, we found the simple correlation between EF and the prevalence of diabetes, so we could not find the causal relationship between them. Second, the study participants were limited to a single institution. In addition, because we limited the participants to those who received LDCT scan for a medical health check-up, there can be a problem in applying this result to the general population. Third, this study confirmed the association between EF thickness and diabetes but a volumetric analysis of EF was not performed. Since volumetric analysis of EF is a time consuming work and requires skilled operators and a specific software program for semi-automated measurement of EF volume, it is difficult to be easily done. Besides, EF thickness shows close correlation with the measurement of the total EF volume [13]. In addition, it is important that we could measure EF thickness in a very simple method without the help of other software programs.

**Conclusion**

Our findings indicate that increased EF thickness – not abdominal fat or total body fat - is independently associated with the prevalence of diabetes in Korean men. In addition, EF could be considered a marker for unfavorable metabolic profile.

**Abbreviations**

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; BMI: Body mass index; CT: Computed tomography; DBP: Diastolic blood pressure; EF: Epicardial fat; GGT: γ-glutamyltransferase; HbA1c: Hemoglobin a1c; HDL: High-density lipoprotein; LDCT: Low dose chest computed tomography; LDL: Low-density lipoprotein; LMCA-fat: Left main coronary artery fat; SBP: Systolic blood pressure; TG: Triglyceride; WC: Waist circumference.

**Competing interests**

The authors declare that they have no competing interests.
Authors’ contributions
HC and KWS conceived the study, participated in its design and coordination; HC and ES researched data, analyzed data and wrote the manuscript; ARB analyzed data and participated and reviewed manuscript; HRP participated in measurements of the epicardial adipose thickness. All authors read and approved the final manuscript.

Acknowledgments
We the guarantors (HC and KWS) take full responsibility of this work as a whole. No funding source is reported.

Author details
1Health Promotion Center, Ewha Womans University Mokdong hospital, Seoul, South Korea. 2Department of Family Medicine, Chaum Hospital, CHA University, Seoul, South Korea. 3Department of Family Medicine, Ewha Womans University Mokdong hospital, Ewha Womans University School of Medicine, Anyangcheon-ro, Yangcheon-gu, Seoul 158-710, South Korea. 4Department of Family Medicine, Ewha Womans University Mokdong hospital, Ewha Womans University School of Medicine, Anyangcheon-ro, Yangcheon-gu, Seoul 158-710, South Korea.

Received: 5 February 2015 Accepted: 15 April 2015
Published online: 03 May 2015

References
1. Festa A, D’Agostino Jr R, Howard G, Mykkkanen L, Tracy RP, Haffner SM. Chonic subclinical inflammation as part of the insulin resistance syndrome: the insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42–7.
2. Arsenault BJ, Lachance D, Lemieux I, Almeras N, Tremblay A, Bouchard C, et al. Viral adipose tissue accumulation, cardiorespiratory fitness, and features of the metabolic syndrome. Arch Intern Med. 2007;167:1518–25.
3. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:3460–6.
4. Bertaso AG, Bertol D, Duncan BB, Foppa M. Epicardial fat: definition, measurements and systematic review of main outcomes. Arg Bras Cardiol. 2013;107(1):e18–8.
5. Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res. 2002;34:616–21.
6. Perseghin G, Lattuada G, De Cobelli F, Esposto A, Belloni E, Ntal I, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology. 2008;47(1):51–8.
7. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Mario U, et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue measurement. Obes Res. 2003;11(2):104–10.
8. Jeong JW, Jeong MH, Yun KH, Oh SK, Park EM, Kim YK, et al. Echocardiographic epicardial fat thickness and coronary artery disease. Curr J. 2007;71(1):536–9.
9. Ahn SG, Lim HS, Joe DY, Kang SJ, Choi BI, Choi SY, et al. Relationship of epicardial fat tissue by echocardiography to coronary artery disease. Heart. 2007;94(3), e7.
10. Iacobellis G, Pellicelli AM, Sharma AM, Grisost B, Barbarini G, Barbaro G. Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. Ann J Cardiol. 2007;99(10):1470–2.
11. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):785–80.
12. Chaovalit N, Somers VK, Pellikka PA, Nhal CS, Lopez-Jimenez F. Subepicardial adipose tissue and the presence and severity of coronary artery disease. Atherosclerosis. 2006;186(2):354–9.
13. Sarem F, Mekhall S, Seifabdikht S, Thonar B, Malik S, Sarlaty T. Quantification of epicardial adipose tissue: correlation of surface area and volume measurements. Acad Radiol. 2011;18(8):977–83.
14. Gotter PA, van Lindert AS, de Vos AM, Meijers MF, van der Graaf Y, Doevedans PA, et al. Quantification of epicardial and peri-cardiac fat using cardiac computed tomography: reproducibility and relation with obesity and metabolic syndrome in patients suspected of coronary artery disease. Atherosclerosis. 2008;197(2):896–903.
15. Abbara S, Desai JC, Cury RC, Butler J, Nieman K, Reddy V. Mapping epicardial fat with multi-detector computed tomography to facilitate percutaneous transendocardial arrhythmia ablation. Eur J Radiol. 2006;57(3):417–22.
16. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the framingham heart study. Circulation. 2008;117(5):605–13.
17. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2015;38 suppS4.
18. Stem MP, Williams K, Gonzalez-Villapando C, Hunt JK, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes care. 2004;27(11):2676–81.
19. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.
20. Nakazato R, Shmillovich H, Tamarappoo BK, Cheng YV, Strom M, Berman DS, et al. Interscan reproducibility of computer-aided epicardial and thoracic fat measurement from noncontrast cardiac CT. J Cardiovasc Comput Tomogr. 2011;5(3):172–9.
21. Iacobellis G, Barbaro G, Genetin HC. Relationship of epicardial fat thickness and fasting glucose. Int J Cardiol. 2008;128(3):424–6.
22. Lin HH, Lee JK, Yang CY, Lien YC, Huang MJ, Wu CK. Accumulation of epicardial fat rather than visceral fat is an independent risk factor for left ventricular diastolic dysfunction in patients undergoing peritoneal dialysis. Cardiovasc Diabetol. 2013;12:127.
23. Iacobellis G, Pistilli D, Guccio M, Leonetti F, Miraldi F, Brancaccio G, et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine. 2005;29(2):251–5.
24. Fuyuse T, Furushashi M, Yuda S, Muranaka A, Kawamukai M, Mita T, et al. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc Diabetol. 2014;13:26.
25. Salmon-Somoza A, Tejeira-Fernández E, Rubio J, Couso E, González-Juareny JR, Eiras S. Coronary artery disease is associated with higher epicardial retinol-binding protein 4 (RBP4) and lower glucose transporter (GLUT4) 4 levels in epicardial and subcutaneous adipose tissue. C不了 Endocrinol (Oxf). 2012;76:151–8.
26. Kichihio I, Takeda M, Hiyoshi A, Hiroshi F, Masanobu S. Relationship between epicardial fat measured by 64-multidetector computed tomography and coronary artery disease. Clin Cardiol. 2011;34(3):166–71.
27. Gokay N, Sinan I, Golhan A, Oguz KU, Rukye N, Korhan S. The relationship between epicardial fat thickness and gestational diabetes mellitus. Diabetol Metab Syndr. 2014;6(1):120.